NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

MrCee-Cee,

Your posts are baseless and your logic doesn’t follow. 😶 …It sounds like you need to do some research—avoid social media and seek your own credible full-context sources of info.

The leadership of this small pre-commercial biotech have been committed to building the prospective value for a significant period of time. Aside from the successful completion of the P3 and the independent peer review that followed, the leadership have coordinated the building of a voluminous MAA, the building of manufacturing capacity, and the building of a comprehensive worldwide patent portfolio, and the list goes on …

Quite arguably, the prospective value of the company is greater today than it has ever been since the company was founded…

The price will follow the real value just as dawn follows night, but the management does not have direct immediate control over all of the market forces, especially at the pre-commercial stage and while on the OTC exchange.

Regulatory developments will be the most determinative factors following the independent peer review, and NWBO is still currently on the OTC. The emerging combo data are also immensely significant and further developments on that front will have an impact. Partnerships are also included in the wide array of possibilities going forward in the near term.

The value of DCVax®-L as a novel cell-based immunotherapy platform technology will be determined by the integrity of the science, and the regulatory process will be the catalyst for its change in price.

As some of the freshly-poured regulatory cement begins to dry into hard stone in the UK and in other nations, further combos and DCVax-Direct will present additional potential for the further expansion of value.

From an investment standpoint, we always hope that the value is greater than the price for the period time preceding their alignment. When will they align? The hands of that clock move with government regulators and with the economics of the pharmaceutical industry, but the science and unmet medical needs comprise the essence of true value.




https://www.prnewswire.com/news-releases/northwest-biotherapeutics-announces-that-a-marketing-authorization-application-has-been-submitted-to-the-uk-mhra-for-dcvax-l-for-glioblastoma-302021038.html